Matthew Reynolds-Tejeda

Matthew studied Biomedical Engineering with a concentration in Nanotechnology at Boston University in 2022, taking graduate courses that covered nanoparticles, DNA/RNA manipulation, and how to utilize thermodynamics for nanomedicine. He gained hands-on experience in researching and formulating nanoparticles for the delivery of a small molecule drug that would treat Age Related Macular Degeneration (AMD). This experience exposed him as to how important delivery vehicles are for effective therapeutics and led him to his role at Greenlight Biosciences, performing research and process development for Lipid Nanoparticles (LNPs) for the delivery of mRNA.